🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Kevan M. Shokat will discuss "Overcoming the Undruggable Nature of K-Ras" in the Opening Plenary Session at the AACR Annual Meeting 2025 (Sunday, April 27). Learn more: brnw.ch/21wS7Cs #AACR25 Kevan Shokat

Clinical Trial Plenary Session on NSCLC at #AACR25 co-chaired by Dr. Everett Vokes and me this Monday, April 28, 10:15am CT: - Zongertinib in #HER2 mutant - SKYSCRAPER-01 (1L atezolizumab + tiragolumab) - JYP0322 in #ROS1 - 1L aumolertinib +/- chemo in #EGFR (AENEAS2)

Happy to see our review out now in Nature Reviews Cancer was fun to co-create this piece with Matthias Valentina and Georg. we aimed to be as contemporary in coverage and forward-looking in outlook on protein degraders mechanisms and cancer therapeutics. nature.com/articles/s4156…

Highly significant selection of the first speaker in the opening plenary at #AACR25: Kevan Shokat talking about the impressive progress in targeting KRas with small molecules. Decades of investing into fundamental science now generating first clinical impact. And much more to come…

Dropping a bloody piece of meat into a tank full of piranhas: here is the structure of RMC-5127, an oral RAS(on)G12V selective non-covalent tricomplex inhibitor disclosed by Anne Edwards/RevMed at #AACR25 AACR. Impressive MedChem work, my prayers are with the process chemists.

ICYMI in Cancer Discovery ahead of today's big clinical plenary at #AACR25 - the preclinical characterization and early clinical proof-of-concept of zongertinib, an irreversible HER2 TKI that spares EGFR signaling and has activity in HER2-driven cancers doi.org/10.1158/2159-8…

Out now in Cancer Discovery and featured #AACR25, we show a combinatorial approach to overcome resistance to RAS(ON) inhibitor monotherapy in PDAC, where use of CDK4/6 inhibitor Palbociclib and CD40 agonist drives therapy-induced senescence & CD4 T cell-dependent tumor-immune equilibrium

We thank the more than 22,000 attendees—including more than 900 virtual attendees—from 81 countries who participated in the AACR Annual Meeting 2025 in Chicago. The #AACR25 hashtag garnered 636 million impressions from 3,852 users on X alone.

#AACR25 Meetings Highlights session: Thanks to Cory Abate-Shen for summarizing the "fearless chemistry" including degraders and glues to drive new drug discovery efforts. Great coverage of the field also by Ingo Hartung and others, much appreciated 👋 See you all at #AACR26

Response and Resistance to RAS Inhibition in Cancer aacrjournals.org/cancerdiscover…

Thoughtful and comprehensive review on progress and perspectives in targeting #RAS oncoproteins in cancer. Just published in Cancer Discovery by Andrew Aguirre and colleagues Dana-Farber News #AACR25 Response and Resistance to RAS Inhibition in Cancer aacrjournals.org/cancerdiscover…

Generation of a biliary tract cancer cell line atlas identifies molecular subtypes and therapeutic targets aacrjournals.org/cancerdiscover…

We’re pleased to share a new, multi-year collaboration with Boehringer Ingelheim that aims to use data and AI to guide biomarker development and patient stratification, develop drug combination hypotheses, support novel target discovery efforts, and more. Learn more:

🚨🥁Exciting Nature Medicine Publication Announcement 👉Hot off the press on this #ClinicalTrialsDay ! Thrilled to share our Nature Medicine paper: "Cancer treatment paradigms in the precision medicine era" 👉We propose 5 BOLD strategic recommendations to modernize cancer

The most impressive data of the day:

🚨 Wow! #ASCO25 ASCO was absolutely massive! 10 NEJM papers published simultaneously 👉 all practice-changing studies ! 🔬✨🧵 See below for these studies 👇@oncoalert

Today, we published new discoveries in a Science Magazine cover story that enable the next generation of molecular glue degrader (MGD) medicines and vastly expand the number of potential targets addressable with MGDs and our QuEEN™ discovery engine: bit.ly/4eBn8Q

1/11 Our study on subclonal immune evasion in non-small cell lung cancer has just been published in Cancer Cell cell.com/cancer-cell/fu…